Biocon’s breast cancer drug to hit markets next month

The company said the drug, which would be manufactured at its biologics facility in Bangalore, will be sold to the patients at a discount.

New Delhi | Updated: January 19, 2014 01:23 AM IST

1 min read

Biotechnology major Biocon will start selling breast cancer drug ‘CANMAb’, developed jointly with US-based Mylan, in the country from next month.
The company said the drug, which would be manufactured at its biologics facility in Bangalore, will be sold to the patients at a discount.
CANMAb will be available at about 25 per cent discount to the current list price of the reference product — Roche’s Herceptin — in India, which is already significantly lower than its price in developed markets, it added.
Herceptin 440 mg, is currently sold at Rs 75,000 in the country. Biocon’s product would be available in 150 mg and 440 mg strengths which costs Rs 57,500. In addition, the medicine would be available in smaller quantities to make it more affordable, Biocon said.